In a report released today, Lisa Lewandowski from Bank of America Securities maintained a Sell rating on Canopy Growth (CGC – Research Report), with a price target of C$0.85. The company’s shares closed today at $0.65.
According to TipRanks, Lewandowski is ranked #1155 out of 8350 analysts.
The word on The Street in general, suggests a Moderate Sell analyst consensus rating for Canopy Growth with a $0.82 average price target, a 26.74% upside from current levels. In a report released on June 12, CIBC also maintained a Sell rating on the stock with a C$0.50 price target.
See the top stocks recommended by analysts >>
CGC market cap is currently C$435.5M and has a P/E ratio of -0.11.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Canopy Growth Corp. engages in the production and sale of medical cannabis. The company offers products including oils and concentrates, soft gel capsules and hemp. It focuses on the treatment of chronic pain, seizures, muscle spasms, nausea, and loss of appetite. The company was founded by Bruce Linton on August 5, 2009 and is headquartered in Smith Falls, Canada.
Read More on CGC:
- Canopy Growth price target lowered to C$0.50 from C$1.75 at CIBC
- Canopy Growth Provides Update on Management Cease Trade Order and Provides Estimate for Reporting of Q4 and FY2023 Financials
- Canopy Growth provides update on management cease trade order
- Here’s What You Missed in Cannabis This Week
- Rising High: Exclusive talk with cannabis market research firm BDSA
